Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia

Leukemia volume 31, pages 747–751 (2017)Cite this article

Subjects

Editorial Note:

Our colleague and dear friend, Professor David Grimwade, senior author of this report, died recently at a tragically young age. David was a gentleman and scholar. He dedicated his career to developing techniques to predict outcomes of persons with acute myeloid leukemia (AML) and was an important contributor to the UK nationwide AML trials.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Grimwade D, Mistry AR, Solomon E, Guidez F . Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat Res. 2010; 145: 219–235.

    Article  CAS  PubMed  Google Scholar 

  2. Grimwade D, Biondi A, Mozziconacci M-J, Hagemeijer A, Berger R, Neat M et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 2000; 96: 1297–1308.

    CAS  PubMed  Google Scholar 

  3. Jovanovic JV, Rennie K, Culligan D, Peniket A, Lennard A, Harrison J et al. Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia. Front Oncol 2011; 1: 35.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016; 374: 422–433.

    Article  CAS  PubMed  Google Scholar 

  5. Yamamoto Y, Tsuzuki S, Tsuzuki M, Handa K, Inaguma Y, Emi N . BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood 2010; 116: 4274–4283.

    Article  CAS  PubMed  Google Scholar 

  6. Boukarabila H, Saurin AJ, Batsché E, Mossadegh N, van Lohuizen M, Otte AP et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 2009; 23: 1195–1206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Koeppel M, van Heeringen SJ, Smeenk L, Navis AC, Janssen-Megens EM, Lohrum M . The novel p53 target gene IRF2BP2 participates in cell survival during the p53 stress response. Nucleic Acids Res 2009; 37: 322–335.

    Article  CAS  PubMed  Google Scholar 

  8. Carneiro FR, Ramalho-Oliveira R, Mognol GP, Viola JP . Interferon regulatory factor 2 binding protein 2 is a new NFAT1 partner and represses its transcriptional activity. Mol Cell Biol 2011; 31: 2889–2901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nyquist KB, Panagopoulos I, Thorsen J, Haugom L, Gorunova L, Bjerkehagen B et al. Whole transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma. PLoS One 2012; 7: e49705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schuh A, Becq J, Humphray S, Alexa A, Burns A, Clifford R et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 2012; 120: 4191–4196.

    Article  CAS  PubMed  Google Scholar 

  11. Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A et al. Mutational analysis of primary central nervous system lymphoma. Oncotarget 2014; 5: 5065–5075.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z et al. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw 2015; 13: 19–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Shimomura Y, Mitsui H, Yamashita Y, Kamae T, Kanai A, Matsui H et al. New variant of acute promyelocytic leukemia with IRF2BP2-RARA fusion. Cancer Sci 2016; 107: 1165–1168.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yeung KT, Das S, Zhang J, Lomniczi A, Ojeda SR, Xu CF et al. A novel transcription complex that selectively modulates apoptosis of breast cancer cells through regulation of FASTKD2. Mol Cell Biol 2011; 31: 2287–2298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sternsdorf T, Phan VT, Maunakea ML, Ocampo CB, Sohal J, Silletto A et al. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell 2006; 9: 81–94.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

DG, ES and EV gratefully acknowledge specialist program grant support from Bloodwise (LLR 13043). RD was supported by a Bloodwise clinical training fellowship (LLR 11036). JVJ was supported by the National Institute for Health Research (NIHR) under its Program Grants for Applied Research Programme (Grant Reference Number RP-PG-0108-10093). MCC was supported by The Spanish Association Against Cancer (AECC). CVF was supported by the Fondation ARC pour la recherche sur le cancer and the Cancéropole PACA (Provence-Alpes-Côte d'Azur). We acknowledge financial support from the Spanish Health Research Program (PI12/02321) and the Red Temática de Investigación Cooperativa en Cáncer (RTICC) RD12/0036/0069, funded by the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER), the European Regional Development Fund (ERDF) (Innocampus; CEI-2010-1-0010), ARC (Association pour la Recherche sur le Cancer), ITMO-cancer and Association Laurette Fugain. This work was enabled by the NIHR Biomedical Research Centre (BRC) based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. In particular, we are grateful to Muddassar Mirza, Efterpi Papouli and Alka Saxena of the BRC Genomics Laboratory, King’s College London, for assistance with the whole exome and targeted sequencing analyses. The views expressed are those of the authors and not necessarily those of the UK National Health Service (NHS), the NIHR or the Department of Health. DG also acknowledges support from the Guy’s and St. Thomas’ Charity.

Author contributions

JVJ, MCC, CV-F, RD, EV, NCG, AAML, YGM, JL and MGD undertook the experimental work. RGS provided clinical data. DG and JVJ designed the study. ES, ED and DG supervised the experimental work. JVJ and DG wrote the first draft of the manuscript. All authors approved the final version of the manuscript.

Author information

Authors and Affiliations

  1. Department of Medical and Molecular Genetics, King’s College London, Faculty of Life Sciences and Medicine, Cancer Genetics Laboratory, London, UK

    J V Jovanovic, R Dillon, E Voisset, E Solomon & D Grimwade

  2. Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC, (USAL-CSIC), Salamanca, Spain

    M C Chillón, N C Gutiérrez, R G Sanz, A A M Lopez & M G Díaz

  3. Centre de Recherche en Cancérologie de Marseille U1068 INSERM, UMR 7258 CNRS, Aix-Marseille Université, Marseille, France

    C Vincent-Fabert & E Duprez

  4. Molecular Oncology Section, Cancer Genetics, Viapath, Guy’s Hospital, London, UK

    Y G Morgan & J Lok

Authors
  1. J V Jovanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M C Chillón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Vincent-Fabert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Dillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Voisset
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N C Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R G Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A A M Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y G Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Lok
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Solomon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E Duprez
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M G Díaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Grimwade
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J V Jovanovic.

Ethics declarations

Competing interests

YM and JL are employees of Viapath, Guy’s Hospital, London. All other authors declare no conflicts of interest.

Additional information

These data were presented in part at the 56th American Society of Hematology meeting, San Francisco, December 2014.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jovanovic, J., Chillón, M., Vincent-Fabert, C. et al. The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia. Leukemia 31, 747–751 (2017). https://doi.org/10.1038/leu.2016.338

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.338

This article is cited by

Search

Advanced search

Quick links